Table 2.
Keratins as prognostic markers in tumor pathology
| Cancer site | Keratin expression pattern |
Detection site |
Prognosis |
|---|---|---|---|
| Biliary duct | High K19 fragment (CYFRA21-1) | Serum | Worse |
| Breast | K5/6, K17 | Tumor | Worse |
| K19 mRNA | CTCsa | Worse | |
| Reduced K18 mRNA | Tumor | Worse | |
| Ubiquitinated K8 and K18 fragments | Tumor | Worse | |
| Colon | Reduced K8, K20 | Tumor | Worse |
| Persistent or higher K18 fragment (M30) after primary tumor resection | Serum | Worse | |
| Kidney | K8, K18 | CTCsa | Worse |
| K7, K19 | Tumor | Better | |
| Liver | K10, K19 | Tumor | Worse |
| Lung | High K18 fragment (M30) | Serum | Worse |
| Pancreas | K20 | Tumor | Worse |
| K20 | Serum | Worse | |
| Prostate | K8, K18, K19 before surgery | Bone marrow | Worse |
| Skin (melanoma) | K18 | Tumor | Worse |
| Stomach | K20 | Peritoneal fluid | Worse |
| Uterus | Loss of K5/K6 | Tumor | Worse |
a
Circulating tumor cells.